TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21452357
Drug: Sham PEMF
Normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham PEMF treatment (identical sham transducers) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.
Study: 21452357
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active and sham PEMF treatments.
Study: 18472364
Drug: First booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: First booster dose (46-70 Gy)
Study: 18472364
Drug: Dose in
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose in the superior constrictor muscle
Study: 10739508
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Study: 10739508
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Study: 10739508
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Study: 10739508
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Study: 10739508
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate increased to 2 mg after 6 months with 2.5 mg medroxyprogesterone acetate
Study: 10739508
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate increased to 2 mg after 6 months with 5 mg medroxyprogesterone acetate
Study: 3658907
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (2 l/min overnight from 22 hrs to 6 hrs)
Study: 21148267
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment programme
Study: 18186995
Drug: Budesonide/formoterol 200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 200/6 microg one puff once daily and as required (active group)
Study: 18186995
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg one puff twice daily plus their own short‐acting beta(2)‐agonist as required (control group)
Study: 16603852
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg each night)
Study: 11115733
Drug: Acute antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute antipsychotic drug administration
Study: 8833207
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg, intravenously)
Study: 8833207
Drug: Clodronate (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1500 mg, intravenously)
Study: 8833207
Drug: Ibandronate (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (0.5-2 mg, intravenously)
Study: 29705445
Drug: Control (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (500 mg capsules containing starch)
Study: 22644009
Drug: Glycophosphopeptical (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycophosphopeptical (1 g every 8 hours for 4 weeks)
Study: 19057628
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Study: 21102963
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of 6 mg non-particulate Celestone
Study: 14765609
Drug: Fluoridated bonding
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated bonding agent with fluoridated composite resin (Group III)
Study: 14765609
Drug: Non‐fluoridated bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐fluoridated bonding agent with fluoridated composite (Group II)
Study: 14765609
Drug: Fluoridated bonding
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated bonding agent with non‐fluoridated composite (Group I)
Study: 18445178
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg) alone
Study: 10391396
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg) in combination with bendrofluazide (2.5 mg)
Study: 1706501
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg/day (group A)
Study: 15759454
Drug: Moxonidine 0.4
Normalized name: moxonidine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.4 mg/day
Study: 7046699
Drug: Flurazepam 15mg
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam 15mg daily for 14 days
Study: 31141445
Drug: Medicine ball
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine ball plyometric training (8 weeks, thrice per week)
Study: 21590273
Drug: 0.6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL of 4% articaine with 1:100,000 epinephrine
Study: 21590273
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL of 4% articaine with 1:100,000 epinephrine
Study: 21590273
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL of 4% articaine with 1:100,000 epinephrine
Study: 19594937
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily (QD)
Study: 19594937
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 100 microg twice daily (BID)
Study: 19594937
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate metered dose inhaler (BDP-MDI) 168 microg BID
Study: 17577003
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg of genistein daily for 24 months
Study: 12186624
Drug: Bicalutamide monotherapy
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide monotherapy
Study: 9726277
Drug: Sustained-release naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release naltrexone (NTX) 206 mg subcutaneous injection
Study: 10439
Drug: Antirheumatic drugs
Normalized name: Quinolines, antirheumatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antirheumatic drugs
Study: 10439
Drug: Pain response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pain response measured using a daily pain chart
Study: 27053574
Drug: Structured patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured patient education ambulatory program combined with weekly sessions of dance therapy
Study: 25095738
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with clopidogrel (75 mg) plus aspirin (300 mg)
Study: 25095738
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin monotherapy (300 mg)
Study: 23358123
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (ExQW) 2 mg
Study: 17400593
Drug: PAIS (Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAIS (Paracetamol in Stroke)
Study: 15200749
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zoledronic acid intravenously yearly
Study: 15200749
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion yearly
Study: 7826961
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (verum)
Study: 3396401
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (single dose)
Study: 3396401
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (1-2 weeks of therapy)
Study: 3396401
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (Group 1)
Study: 3396401
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (Group 2)
Study: 29457876
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg single dose
Study: 27297718
Drug: Curcumin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1000 mg/d)
Study: 21122699
Drug: ERN/LRPT 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT 1 g
Study: 11814493
Drug: Vaginal metronidazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal metronidazole, 37.5 mg twice daily for 5 days
Study: 11814493
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel twice daily for 5 days
Study: 6994789
Drug: Inert preparation
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert preparation (placebo)
Study: 31552981
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg free EA
Study: 31552981
Drug: 237 mL
Normalized name: ALCOHOL 189.6 mL in 237 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 237 mL PomJ (∼120 mg of EA)
Study: 9815298
Drug: All arms
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All arms received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15.
Study: 7708002
Drug: octreotide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide (daily doses between 100 and 1000 micrograms)
Study: 31315910
Drug: O-sulfo-l-tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-sulfo-l-tyrosine
Study: 26305143
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tolterodine ER
Study: 26305143
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tolterodine ER
Study: 7851032
Drug: Lisinopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (mean dose: 6.4 +/- 4 mg) for 6 months
Study: 29111784
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) only
Study: 29111784
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bright Light Therapy (BLT) and Wake Therapy (WT)
Study: 28195995
Drug: TX-004HR (4-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-004HR (4-, 10-, and 25-μg)
Study: 23446684
Drug: Pridopidine 90
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 90 mg/day
Study: 18440821
Drug: Everolimus (0.75-10mg)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (0.75-10mg) daily for 21 days
Study: 12648202
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of hyperbaric bupivacaine + 10 microg fentanyl (B3F)
Study: 12648202
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of hyperbaric bupivacaine (B4)
Study: 16198237
Drug: Edaravone (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (administered to 27 patients: GIa, n = 13; GIIa, n = 14)
Study: 2321570
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (65 mg/d for 2 weeks, 5 mg/d for 4 weeks, 605 mg/d for 3 weeks, 5 mg/d for 4 weeks, average 375 mg/d for 1 week)
Study: 28296581
Drug: Alectinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 300 mg orally twice per day
Study: 26255281
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation (800 mg BA + 8 g dextrose, 4 doses/day for 28 days)
Study: 26255281
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 8 g dextrose, 4 doses/day for 28 days)
Study: 20947819
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg/d)
Study: 20947819
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 g/d)
Study: 16973786
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) over 6 months
Study: 16973786
Drug: Monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly monitoring
Study: 9631952
Drug: Pergolide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.05 mg BID) for 8 days
Study: 23314060
Drug: Biological pathway
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological pathway analysis
Study: 14747190
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet/day)
Study: 18361342
Drug: Oral-B Triumph
Normalized name: Triumph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Triumph
Study: 18361342
Drug: Combined overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined overall treatment effect from two studies
Study: 12708602
Drug: SB-LOT (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-LOT (90 mg coumarin + 540 mg troxerutin/d)
Study: 8715321
Drug: Technique of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique of drop administration taught to patients
Study: 1396198
Drug: Nimorazole 4G
Normalized name: nimorazole
DrugBank: Nimorazole (DB12172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole 4G in two equally divided doses 24 hours apart (2GBD)
Study: 24831919
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (BG: 70‐110 mg/dL)
Study: 24831919
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic control (BG: 70‐180 mg/dL)
Study: 19644691
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) treatment and exercises
Study: 16008114
Drug: Korodin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korodin (25 drops, applied once, followed by daily 3 x 25 drops for 7 days)
Study: 16008114
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single application and daily treatment for 7 days)
Study: 10368079
Drug: Oxcarbazepine (OCBZ)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OCBZ) 1,200 mg/day
Study: 29114894
Drug: INCS in
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INCS in monotherapy
Study: 26575323
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg salmeterol treatment
Study: 26575323
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg salmeterol treatment
Study: 22581070
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (cognitive remediation + functional skills training)
Study: 18590350
Drug: XP-828L (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP-828L (800 mg daily for 56 days)
Study: 14628497
Drug: Androgen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen supplementation therapy (testosterone replacement therapy)
Study: 27781372
Drug: Sufentanil Sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil Sublingual Tablet 30 mcg (SST)
Study: 24627339
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (1 mg capsule)
Study: 24627339
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (1 mg capsule)
Study: 25263017
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with eGFR <30 mL/min
Study: 25263017
Drug: VTE patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE patients with eGFR >90 mL/min
Study: 25263017
Drug: VTE patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE patients with eGFR 60-89 mL/min
Study: 25263017
Drug: VTE patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE patients with eGFR 45-59 mL/min
Study: 25263017
Drug: VTE patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE patients with eGFR 30-44 mL/min
Study: 25263017
Drug: VTE patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE patients with eGFR 15-29 mL/min
Study: 19202330
Drug: B-vitamin therapy
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin therapy (folic acid 2 mg, vitamin B(6) 25 mg, vitamin B(12) 0.5 mg)
Study: 15247115
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine hydrochloride
Study: 15247115
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine hydrochloride
Study: 15247115
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine hydrochloride
Study: 7782117
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg once daily
Study: 6367784
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg intravenously followed by 200 mg daily for three months)
Study: 30049498
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care group without computer/tablet/smartphone (n=49)
Study: 23112075
Drug: Tricot compression
Normalized name: Tricor
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricot compression bandage plus intermittent cryocompression therapy 15 times for 30 minutes
Study: 20105043
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin (PPI) (Exubera)
Study: 20105043
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (BI) (insulin glargine)
Study: 20105043
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin (PPI)
Study: 15851890
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg EREM
Study: 15851890
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg EREM
Study: 15851890
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg EREM
Study: 14594344
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 20 mg
Study: 14594344
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 40 mg
Study: 14594344
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 80 mg
Study: 14594344
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of testosterone undecanoate
Study: 3900303
Drug: Metoclopramide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide alone (1.0 to 3.0 mg/kg)
Study: 3900303
Drug: Metoclopramide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide with adjunct dexamethasone (20 mg) at a fixed dose of 2.0 mg/kg
Study: 29197867
Drug: Topical coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coconut oil (5 mL/kg) twice daily for 21 days
Study: 29197867
Drug: Topical coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coconut oil
Study: 24576202
Drug: Ropivacaine 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.50% (50 mL)
Study: 23027801
Drug: Algorithm-consistent warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-consistent warfarin dosing
Study: 16969361
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily and Metformin 500 mg three times daily
Study: 30698554
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug therapy)
Study: 18245148
Drug: Etanercept (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (an IgG1‐TNF p75 receptor fusion protein), administered once weekly for 12 weeks
Study: 15291188
Drug: Diaspirin cross-linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaspirin cross-linked hemoglobin (DCLHb) solution (50 mg/kg or 35 mL for a 70-kg patient)
Study: 9519099
Drug: Sulpiride (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (600 mg/day)
Study: 8368459
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate 5.2 mg four times daily
Study: 30198828
Drug: Yeast beta-glucan
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast beta-glucan (900 mg daily for 16 weeks)